Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma

NCT02867332 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT02867332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02867332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma
Lead sponsor
Peking University
Phase
Phase 1
Overall status
Withdrawn
Start date
November 30, 2016
Completion date
November 30, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma